Please assess the completion status of the following clinical trial:

Trial Title: Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has documented chronic HCV GT1, GT4, or GT6 (with no evidence of non-typeable or mixed genotype) infection~* Meets clinical criteria for presence or absence of cirrhosis based on liver disease staging assessment~* Is abstinent or uses acceptable method(s) of contraception~Exclusion Criteria:~* Has evidence of decompensated liver disease~* Is coinfected with hepatitis B virus or human immunodeficiency virus (HIV)~* Shows evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC~* Has a clinically-relevant drug or alcohol abuse within 12 months of screening~* Is pregnant or breast-feeding~* Has any condition or abnormality that might confound the results of the trial or pose an additional risk to the participant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate Treatment Group (ITG): Grazoprevir/Elbasvir (Type: EXPERIMENTAL): Participants receive a grazoprevir/elbasvir FDC tablet once daily (q.d.) by mouth during a 12-week Active Treatment period (Week 1 to Week 12) and are followed-up for 24 weeks to Week 36.
- Deferred Treatment Group (DTG): Placebo > Grazoprevir/Elbasvir (Type: PLACEBO_COMPARATOR): Participants receive a placebo tablet q.d. by mouth for 12 weeks (placebo treatment period). After a 4-week Follow-Up period, participants receive open-label grazoprevir/elbasvir FDC during a 12-week Active Treatment period (Week 16 to Week 28). Participants are then followed-up for 24 weeks to Week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).